Neurofilament Light Chain and MS Prognosis, Treatment Effect, and Anticipation of Disease
This program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC.
Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, contextualize data from large studies regarding the utilization of neurofilament light chain.
EP: 1.The Value of Biomarker in Multiple Sclerosis
EP: 2.Evolving Methods of Multiple Sclerosis Diagnosis
EP: 3.Assays to Detect Neurofilament Light
EP: 4.Challenges and Opportunity With MRI
EP: 5.Neurofilament Light Chain and Acute Gadolinium Enhancing Lesions
EP: 6.Exploring Potential Applications of Neurofilament Light Chain in MS Prognosis and Care
EP: 7.Practical Considerations for the Use of Neurofilament Light Chain and MRI
EP: 8.How to Address Increasing Neurofilament Light Chain Levels
EP: 9.Weighing Treatment Decisions Based on Neurofilament Light Chain Levels
EP: 10.Monitoring Patients After a Change in Treatment Regimen
EP: 11.Assessing Lesion Types With MS Biomarkers
EP: 12.Neurofilament Light Chain and MS Prognosis, Treatment Effect, and Anticipation of Disease
EP: 13.The CLIMB Study
EP: 14.Reimbursement for MRI
EP: 15.Understanding the Underlying Progression of Multiple Sclerosis
EP: 16.Biomarkers, Patient Communication, and the Future of Care
EP: 17.Question and Answer about Neurofilament Light Chain and Other MS Biomarkers
In this segment, Ahmed Obeidat, MD, PhD, provides a concise summary of recent studies that investigated the correlation between neurofilament light chain (NFL) levels and long-term disability in multiple sclerosis (MS) patients. He mentions that these studies indicate a potential role for NFL in predicting disability accumulation over several years, challenging the previous assumption that NFL primarily correlates with inflammation rather than the neurodegenerative process.
Ahmed Obeidat, MD, PhD, also highlights that the predictive power of NFL seems more robust in the relapsing MS population compared to those with progressive MS. He emphasizes the accumulating evidence from various cohorts and countries supporting the potential use of NFL, along with other biomarkers, in predicting long-term outcomes on a population level.
Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.
